Eli Lilly Acquires Merida for $2.9B | Pharma and Biotech Daily

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world.

The current landscape in the pharmaceutical and biotech industries is a tapestry of dynamic mergers, clinical trial advancements, regulatory approvals, and strategic partnerships. A major highlight is Eli Lilly's acquisition of Merida Biosciences for up to $2.9 billion. This move exemplifies the industry's strategic focus on expanding portfolios specifically in...